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Solving Glycosylation Disorders:
Fundamental Approaches Reveal Complicated Pathways
Hudson H. Freeze,1,* Jessica X. Chong,2 Michael J. Bamshad,2 and Bobby G. Ng1Over 100 human genetic disorders result frommutations in glyco-
sylation-related genes. In 2013, a new glycosylation disorder was
reported every 17 days. This trend will probably continue given
that at least 2% of the human genome encodes glycan-biosyn-
thesis and -recognition proteins. Established biosynthetic path-
ways provide many candidate genes, but finding unanticipated
mutated genes will offer new insights into glycosylation. Simple
glycobiomarkers can be used in narrowing the candidates identi-
fied by exome and genome sequencing, and those can be validated
by glycosylation analysis of serum or cells from affected individ-
uals. Model organismswill expand the understanding of thesemu-
tations’ impact on glycosylation and pathology. Here, we high-
light some recently discovered glycosylation disorders and the
barriers, breakthroughs, and surprises they presented. We predict
that some glycosylation disorders might occur with greater fre-
quency than current estimates of their prevalence. Moreover, the
prevalence of some disorders differs substantially between Euro-
pean and African Americans.Introduction
A decade or two from now, biomedical research teams will
chuckle as they glance back at the ‘‘old days’’ (the present)
of glycophobia—that breath-holding response to finding
out that a project or caring for an individual requires famil-
iarity with glycosylation. The disappearance of glycopho-
bia will be due in part to the recognition that disorders
involving glycosylation pathways are relatively common
and represent phenotypes cared for across medical spe-
cialties. The rapid pace of the discovery of disorders that
affect protein glycosylation is bolstering this integration
of glycobiology into mainstream medicine. So far, as of
2013, a new glycosylation disorder has been reported, on
average, every 17 days. This trend is being driven by tech-
nological advances in next-generation sequencing coupled
with improved annotation of exome and/or genome
sequencing results (Figure 1).1–4 However, it remains a sub-
stantial challenge to characterize the impact of putative
disease-causing mutations on the biochemical and physio-
logical functions of the cells and/or organ systems that
they affect.
Glycosylation as a posttranslational modification occurs
in at least ten distinct biosynthetic pathways: some add a
single sugar, whereas others add hundreds to multiple pro-
tein and lipid acceptors.5 Distributed over thousands of
proteins, thousands of glycan structures are now known,
and all are engineered by nontemplate-driven assembly1Human Genetics Program, Sanford Children’s Health Research Center, Sanfo
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The Americguidelines.1,6,7 In this review, we define a glycosylation dis-
order as a genetic defect that alters the structure or biosyn-
thesis of glycans (sugar chains) in one ormore biosynthetic
pathways. We highlight some of the approaches, break-
throughs, barriers, and surprises contained in several
recently discovered glycosylation disorders. Of course,
any discussion of specific glycosylation disorders requires
that we also provide some pertinent biochemical back-
ground information. In writing this review, we hope to
convey the clinical diversity of glycosylation disorders,
the possible involvement of suspected protein complexes,
and the advantages of studying pathways that modify only
a few specific proteins.
Essentials of Glycosylation Pathways
Here, we review several glycosylation pathways to provide
the necessary context to enable the understanding, from a
biochemical standpoint, of the different classes of glycosyl-
ation disorders. The discovery of glycosylation disorders
predictably includes the implication of genes encoding
proteins required for precursor sugar activation: glycosyl-
transferases, glycan-modifying glycosidases, and trans-
porters. Finding defects in expected genes invigorates
and expands the current understanding of those pathways.
In addition, genes involved in incompletely understood
biosynthetic pathways or trafficking of the glycosylation
machinery can also be revealed. Details about the relevant
glycosylation pathways can be found in Essentials of Glyco-
biology (see Web Resources). In addition to inherited
defects that alter glycan structure, pathological conditions
such as cancer and inflammation, as well as physiological
conditions such as pregnancy, can induce changes in
glycosylation patterns.8–11
A glycosylation pathway is defined by the first sugar
(monosaccharide) added to a protein or lipid. Nine glyco-
sylation pathways operate in the mammalian endoplasmic
reticulum (ER) and Golgi apparatus.12–14 We describe six of
these pathways because of their involvement in recently
discovered glycosylation disorders. Notably, each requires
activated nucleotide sugars to contribute the building
blocks for glycans; therefore, many of these substrates ser-
vice multiple pathways. Each pathway has a dedicated set
of biosynthetic glycosyltransferases, but multiple path-
ways can share many of the same transferases that add
sugars farther away from the protein or lipid linkage.15rd Burnham Medical Research Institute, La Jolla, CA 92037, USA; 2Depart-
y of Human Genetics. All rights reserved.
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Figure 1. Identification of Glycosylation-
Related Disorders
The graph shows the cumulative number
of human glycosylation disorders in
various biosynthetic pathways and the
year of their identification. In most cases,
the year indicates the definitive proof of
specific linked genes or causative muta-
tions. Prior to ~2000, discovery of glycosyl-
ation disorders was based on compelling
biochemical evidence and confirmed by
the identification of mutations in the
genes. In 2013 alone, a genetically proven
glycosylation disorder was reported, on
average, every 17 days.Common to all pathways is the need for cytoplasmic
monosaccharides to be activated to the nucleotide sugars;
the activated monosaccharides are then either utilized in
the cytoplasm or transported into the Golgi. One notable
exception is the formation of CMP-sialic acid, which is
created in the nucleus and exported to the Golgi.16 Defects
in both sugar activation and donor transport,13,16 as well as
mutations in genes encoding glycosyltransferases, underlie
many human disorders.
N-Glycosylation: Modification within the ER and
Golgi
The process of N-glycosylation begins for thousands of
mammalian acceptor proteins in the ER during or soon
after the synthesis of nascent proteins containing Asn-
X-Ser, Asn-X-Thr, or Asn-X-Cys consensus sequences.17
A series of activated precursors—uridine diphosphate
(UDP) N-acetylglucosamine (UDP-GlcNAc), guanosine
diphosphate (GDP) mannose (GDP-Man), dolichol phos-
phate (Dol-P) mannose (Dol-P-Man), and Dol-P glucose
(Dol-P-Glc)—provide three sugars that are added sequen-
tially to a Dol-P acceptor embedded in the ER mem-
brane.17 This well-ordered process produces a tribranched
Glc3Man9GlcNAc2 glycan on the luminal side of the ER.
The glycan from this lipid (dolichol)-linked oligosaccha-
ride (LLO) precursor is then transferred en bloc to pro-
teins. Synthesis and transfer of the glycan to proteins
requires at least 40 known gene products.17 Figure 2
shows this portion of the N-linked glycosylation pathway,
genes, and known defects. After protein-bound chains
are remodeled (processed) in the ER by excising glucose
(and some mannose), proteins move to the Golgi, where
additional mannose residues are often removed and vari-162 The American Journal of Human Genetics 94, 161–175, February 6, 2014able amounts of GlcNAc, galactose,
fucose, and sialic acid are sometimes
added in different linkages and in
multiple branching patterns.17 Some
N-glycans receive sulfate or phos-
phate esters. The glycoproteins are
trafficked to various intracellular
compartments, to the cell surface,
or into the extracellular matrix andbeyond. Generating the complex library of processed
N-glycans probably requires at least 35 known gene prod-
ucts. The functional importance of a specific N-glycan and
its protein is unpredictable, but it ranges from trivial to
essential.18
O-Glycosylation: Multiple Pathways Generate
a Diversity of Glycans
O-glycosylation involves covalent modification of Ser or
Thr residues, including several different sugar-amino-acid
linkages.
N-acetylgalactosamine (O-GalNAc)-containing glycans
are often found on mucins or mucin-like proteins.
The glycans are densely packed in brush-like clusters
on mucins that protect epithelial cell surfaces.19 How-
ever, more recent work has shown that the great
majority of the hundreds of O-GalNAc-containing pro-
teins are not heavily glycosylated but instead are modi-
fied by just a few scattered O-GalNAc glycans.19 Some,
such as FGF23, rely on O-GalNAc for their function,
but there are very few glycosylation disorders in this
pathway.20
This might reflect the high redundancy of the genes en-
coding initiating O-GalNAc transferases. In contrast to the
N-glycosylation and O-GalNAc pathways, which contain
numerous protein clients, the O-mannose-based pathway
is highly selective and only has a few known targets,21
most notably a-dystroglycan (a-DG). Disruption of a-DG
O-mannosylation nearly always results in disease.22
Indeed, the identification of a-dystroglycanopathies
helped to identify this pathway. Unfortunately, our knowl-
edge of the glycan structures and biosynthetic pathways
of the O-mannose-based pathway remains incomplete.
Figure 2. N-Linked Glycosylation Pathway Showing Activation of Precursor Molecules and Synthesis of Dolichol-P-P-GlcNAc2-
Man9Glc3 and Transfer to Protein
Early steps in the N-linked pathway require conversion of the lipidmolecule polyprenol to the oligosaccharide carrier molecule dolichol,
which serves as a scaffold for LLO.Monosaccharides activated in the cytoplasm are used as substrates for several glycosyltransferases that
extend the growing chain. Once dolichol-P-P-GlcNAc2Man5 is formed, it flips into the ER lumen and is further extended to the final
product with Dol-P-Man and Dol-P-Glc as donors for different mannosyl- and glucosyl-transferases, respectively. The oligosaccharyl-
transferase complex then transfers the completed structure onto nascent polypeptides. The processing of N-glycans is not shown.
Genetic defects within this pathway are shown by an X. This figure was adapted from Figure 42.1 in Essentials of Glycobiology, Second
Edition from Cold Spring Harbor Laboratory Press and is used with permission.We know, however, that selected Ser or Thr residues use
Dol-P-Man and a POMT1-POMT2 complex to add
mannose;23,24 details about the biosynthesis of more com-
plex glycans and their structures have been slow to emerge.
A set of glycans contain mannose-6-phosphate
(Man-6-P) along with a glycosaminoglycan-like polymer
composed of alternating a1,3-xylose and b1,3-GlcUA resi-
dues.25 Man-6-P is modified to an unknown diester,26 but
the order, prerequisite glycan structures, and donor sub-
strates remain undefined. Disorders caused by mutations
in genes including FKTN (fukutin [MIM 607440]) and
FKRP (MIM 606596) define glycosylation-related muscular
dystrophies, but these ‘‘orphan’’ glycosyltransferases lack
defined donors and acceptors.24
Notch genes are well known for their roles in develop-
ment and are conserved from Drosophila to humans.27
Less appreciated are the highly conserved epidermal
growth factor (EGF) repeats within Notch-related proteins;
these contain a series of consensus-sequence motifs that
specify O-glycosylation28 covering three distinct path-
ways: O-a-fucose, O-b-GlcNAc, and O-b-glucose. TheThe AmericO-a-fucose-based glycans are well known because they
are the recipients for the Fringe family of b-GlcNAc transfer-
ases.29 The presence of these three O-glycan types on
Notch-related proteins can strongly influence Notch
signaling. A separate O-fucosyltransferase specifically rec-
ognizes a distinct set of proteins with thrombospondin
type I repeats; those O-a-fucose glycan chains are further
extended with one to two glucose units.12,30
Recent work has shown that in addition to undergoing
O-a-fucose and O-b-glucose modification, Notch proteins
can undergo an O-b-GlcNAc modification.31,32 This modi-
fication occurs in the Golgi and is distinct from cyto-
plasmic O-b-GlcNAc modification, sometimes called
O-GlcNAcylation.33
Glycosylphosphatidylinositol-Anchor Pathway
Glycosylphosphatidylinositol (GPI) anchors are lipid-
based glycans that undergo stepwise assembly on phos-
phatidylinositol in the ER membrane and remodeling in
the Golgi (Figure 3).34,35 Assembly begins with the trans-
fer of GlcNAc by a large protein complex on thean Journal of Human Genetics 94, 161–175, February 6, 2014 163
Figure 3. GPI-Anchor Synthetic Pathway
The initial two steps of GPI-anchor biosynthesis in mammalian cells require the formation of GlcNAc-PI and then de-N-acetylation of
GlcNAc-PI to form GlcN-PI, which occurs on the cytoplasmic face of the ER. GlcN-PI then flips into the ER lumen, where further exten-
sion of the glycan occurs by the addition of mannose and ethanolamine phosphate. The completed structure is transferred to multiple
acceptor proteins. One of the acyl chains is removed. The GPI-anchored proteins move to the Golgi, where one of the acyl chains is
removed and another is added. Genetic defects with in this pathway are noted in red.cytoplasmic face (PIGA) and continues with the unusual
step of GlcNAc de-N-acetylation (via PIGL) to form glucos-
amine (GlcN). A flip to the luminal side then adds an
additional acyl chain to inositol (via PIGW) and extends
the GlcN by two mannose residues (via PIGM and
PIGV), ethanolamine phosphate (via PIGN), another
mannose (via PIGB), and two additional ethanolamine
phosphates (via PIGO and PIGF).36 Newly made proteins
that carry an appropriate C-terminal amino acid sequence
then serve as acceptors for the sugar-lipid unit. A multisu-
bunit transamidase (PIGT) complex removes the peptide
from the client proteins and substitutes the amino group
from ethanolamine. The acyl chain added by PIGW is
removed by PGAP1, PGAP5 cleaves the ethanolamine
phosphate added by PIGF, and the anchored proteins
are transported to the Golgi, where fatty-acid remodeling
occurs. PGAP3 removes an unsaturated fatty acid and re-
places it with a saturated fatty acid by using an acyltrans-
ferase and a noncatalytic subunit PGAP2, which is
thought to help recruit the fatty-acid donor (Figure 3).36
Along with glycosphingolipids and cholesterol, GPI-an-
chor-containing proteins cluster into lipid rafts on the
cell surface.37 Better characterized GPI-anchored clients164 The American Journal of Human Genetics 94, 161–175, Februaryinclude alkaline phosphatase (ALP), CD55, CD16b, and
CD5938 (Table 1).
Lessons from the Discovery of New Mendelian
Disorders
The identification of individuals who harbor potentially
pathogenic mutations in genes involved in glycosylation
requires verification of an effect on glycosylation. This vali-
dation has also provided biochemists and glycospecialists
with crucial insights into and perspectives on glycosyla-
tion itself. Several examples below from different pathways
illustrate this concept. The most important point to make
here is that many rare glycosylation disorders were identi-
fied because biochemical analysis strongly pointed to defi-
ciencies in one or more glycosylation pathways. The same
tools that helped focus analysis on the most likely gene
candidates also provided functional approaches to vali-
dating the pathological impact of specific variants.
Defects in N-Linked or Multiple Glycosylation
Pathways
The majority of glycosylation disorders affect either the
N-glycosylation pathway or multiple pathways (Table S1,6, 2014
Table 1. Biochemical Markers for Various Glycosylation Pathways
Disorder Type Biomarker(s) Sample Type
N-glycan trasnferrin39,40 serum, plasma
GPI anchor CD59, CD55, CD16b,
ALP, and a GPI-binding
toxin, aerolysin
(FLAER)41,42
granulocytes,
platelets,
fibroblasts
a-dystroglycanopathies a-DG antibody (IIH6)43 muscle biopsy,
fibroblastsavailable online).1,12,13 Most of these disorders follow
autosomal-recessive inheritance patterns, but X-linked,
dominant, and de novo mutations have also been identi-
fied (Table S2). The best-known and most prevalent type
of autosomal-recessive congenital disorder of glycosylation
(CDG) is PMM2-CDG (previously called CDG-Ia [MIM
212065]), which is caused by mutations in PMM2 (MIM
601785) and occurs at an estimated frequency of
~1/20,000. The encoded enzyme catalyzes the conversion
of Man-6-P to Man-1-P, which provides activated precur-
sors to at least four different glycosylation pathways: the
N-linked, O-mannose, GPI-anchor, and C-mannosylation
pathways. Nearly all studies have focused on the delete-
rious effects of PMM2mutations on N-glycosylation alone,
but other pathways could be affected. Over 100 mutations
have been found in this gene,44 and the most prevalent,
c.422G>A (p.Arg141His) (RefSeq NM_000303.2), has a car-
rier frequency of ~1/60–1/70 in Europe,45 but it is lethal in
the homozygous state.
Glucose, Glycogen, and Glycosylation
Most biochemical and genetic studies of ‘‘carbohydrate
metabolism’’ have focused on glucose and glycogen
because of their central role in energy metabolism. More
than a dozen glycogen-storage disorders, which impair
synthesis or degradation of glycogen, have been
described.46,47 The quantitative contributions of glucose,
other dietary oligosaccharides, de novo synthesis, and
salvage pathways to each component sugar are not well
known47 but most likely vary among different cells and tis-
sues. However, clues about glycosylation pathways and
glucose metabolism emerged recently with the discovery
of N- and O-glycosylation abnormalities in glycogen-stor-
age disease Ib (MIM 232220), caused by mutations in the
genes that encode glucose-6-phosphate translocase48
(SLC37A4 [MIM 602671]) and glucose-6-phosphatase 3
(G6PC3 [MIM 611045]). Loss of function of either has pro-
found effects on neutrophils, leading to neutropenia as a
result of ER stress and subsequent apoptosis.48 Abnormal
glycosylation in particular affects gp91(phox), the elec-
tron-transporting NADPH oxidase component that is
needed for the oxidative burst release of reactive oxygen
species required to kill surrounding pathogens. Many N-
and O-glycans from these cells lack galactose and sialic
acid.48 However, it is unclear whether N-glycosylation sites
are fully occupied.The AmericA recent study characterized the clinical phenotype, mo-
lecular basis, and treatment of several of the 19 individuals
harboring mutations in PGM1 (MIM 171900), which en-
codes phosphoglucomutase 1 (Glc-1-P4 Glc-6-P).49 This
enzyme is critical for sending metabolic glucose toward
UDP-glucose and glycogen synthesis and catabolizing
glycogen-derived glucose. Affected individuals displayed
a broad range of clinical findings, including split uvula
and/or cleft palate, hypoglycemia, hepatopathy and coa-
gulopathy to malignant hyperthermia, dilated cardiomy-
opathy, and cardiac arrest. Fibroblasts from affected indi-
viduals showed deficient N-glycosylation and decreased
levels of UDP-galactose. Notably, galactose treatment
normalized nucleotide sugar levels and resulted in measur-
able clinical improvement.50 This disorder links two previ-
ously distinct classes of conditions, (1) glycogen synthesis
and degradation and (2) glycosylation. The clinical impor-
tance of this link is that a simple measurement of glycosy-
lated serum transferrin could allow physicians to prescribe
galactose early on with the hope of a better clinical
outcome. PGM1 deficiency is unique among glycosylation
disorders because glycoproteins have both unoccupied
N-glycosylation sites, and among the glycans that are
added, they sometimes also lack galactose and sialic acid.
Whereas galactose supplements could increase UDP-galac-
tose and explain improved galactose addition, it remains
unclear how galactose can restore full N-glycosylation
site occupancy.
Delivery of UDP-Galactose into the Golgi
The value of performing a biochemical analysis to guide
interpretation of exome sequencing results is illustrated
by the discovery that de novo mutations in the X-linked
UDP-galactose transporter SLC35A2 (MIM 314375) cause
CDG type IIm (MIM 300896).51 Analysis of transferrin
glycosylation status in an infant with developmental
delay, hypotonia, seizures, and brain malformations re-
vealed a unique pattern suggesting a deficiency of galac-
tose addition to the sugar chain. Analysis of a limited num-
ber of candidate genes involved in galactose addition led to
the identification of a mutation in SLC35A2, which en-
codes the only known UDP-galactose transporter that de-
livers the activated substrate into the Golgi. Two other in-
dividuals who had undergone exome sequencing but for
whom no causative variant(s) could be found shared the
same abnormal transferrin pattern. Standard filtering of
exome data had originally excluded SLC35A2, but manual
review of the BAM files showed that both individuals were
mosaic for SLC35A2 mutations. Given the high frequency
of de novo mutations emerging from large exome
sequencing projects, it is important to realize that somatic
mosaicism could be overlooked unless it is specifically
sought. This might not be possible in all cases, but
biochemical studies can help focus on appropriate candi-
date genes. In the case of SLC35A2 mutations, the
biochemical analysis was critical, but surprisingly, trans-
ferrin glycosylation normalized in all three cases by thean Journal of Human Genetics 94, 161–175, February 6, 2014 165
age of 3 years without corresponding clinical improve-
ment.51 This finding should encourage the use of trans-
ferrin testing in early infancy, given that a delay could
cause the biochemical abnormality to be missed.
Defects in Golgi Homeostasis
Disruption in Golgi homeostasis via abnormal architecture
or trafficking has been shown to cause various glycosyla-
tion disorders.1,12 It is not surprising that disruption of
the intra-Golgi pH machinery would also disrupt homeo-
stasis. Evidence of this was shown by the identification
that pathogenic mutations in ATP6V0A2 (MIM 611716),
which encodes one subunit of a vacuolar ATPase, cause
another CDG that is characterized by abnormal wrinkly
skin, short limbs, and CNS abnormalities (MIM 219200
and 278250).52,53 The ATPase complex regulates intrave-
sicular pH, and the mutations disrupt trafficking of
resident Golgi glycosyltransferases and general Golgi
homeostasis,52 resulting in a partial absence of sialic acid
and galactose on glycans. Similarly, mutations in
TMEM165 (also called TPARL [MIM 614726]) cause
another glycosylation disorder (MIM 614727)54 that im-
pairs normal vacuolar pH and the addition of galactose
and sialic acid to N- and O-glycans, suggesting a Golgi-
homeostasis defect.55 TMEM165 encodes a highly
conserved protein that is predicted to have six mem-
brane-spanning regions; it is most likely a Golgi-localized
Ca2þ/Hþ antiporter. Patch-clamp studies indicate that
TMEM165 is involved in both Ca2þ transport and pH alter-
ation. The results of these studies suggest that, in addition
to examining pH, we must also consider that Ca2þ plays a
direct or indirect role in glycosylation and in Golgi func-
tion and homeostasis.54,56
Myasthenia Syndromes: Unexpected Mutations
in Glycosylation Genes
Defective glycosylation can also cause congenital myas-
thenia syndromes (CMSs),57 which impair signal transmis-
sion at the neuromuscular synapse.57 Defects can occur at
the synapse or at presynaptic or postsynaptic locations, the
latter of which compose the great majority of CMSs.58
Among the group of postsynaptic disorders, some are
caused bymutations in one of the genes encoding the pen-
tameric acetylcholine receptor (AChR) subunits (CHRNE
[MIM 100725]), which inhibit assembly of the com-
plex.57 More than a decade ago, CHRNEmutations that de-
stroyed a glycosylation site and diminished protein levels
(congenital myasthenic syndrome associated with AChR
deficiency [MIM 608931]) were found. Subsequently, 13
unrelated families affected by limb-girdle CMS were found
to have mutations in glutamine-fructose-6-phosphate
transaminase 1 (GFPT1 [MIM 138292]), whose protein
product is required for UDP-GlcNAc synthesis;59 later,
another eleven cases were found.60 Knockdown of the ze-
brafish ortholog gfpt1 altered muscle-fiber morphology
and impaired neuromuscular-junction development in
embryos.59 Surprisingly, some GFPT1 mutations had no166 The American Journal of Human Genetics 94, 161–175, Februaryeffect on enzymatic activity, suggesting that the organiza-
tion or localization of the enzyme in the cytoplasm is
important for normal function. Muscle biopsy and
cultured myotubes from affected individuals showed
reduced cell-surface AChR; similarly, small interfering
RNA (siRNA)-mediated silencing of GFPT1 also reduced
AChR levels.61
Glycosylation defects were also identified in five individ-
uals with an undiagnosed form of limb-girdle CMS
with tubular aggregates (MIM 614750). Whole-exome
sequencing of these individuals identified mutations in
DPAGT1 (MIM 191350), which encodes the first enzyme
in LLO synthesis, dysfunction of which also causes
CDGs.62,63 However, these CMS-affected individuals had
a much milder phenotype than previously reported for
DPAGT1-CDG cases.64 Muscle biopsies and cultured myo-
blasts from several cases showed reduction of AChR at the
endplates. Additionally, siRNA knockdown of DPAGT1
also decreased expression of three AchR subunits (alpha,
gamma, and epsilon). DPAGT1 and GFPT1 mutations
cause AChR instability, pointing to a causal role for faulty
N-glycosylation of the receptors. This concept is supported
by the identification of CMS-affected individuals with mu-
tations in ALG14 (MIM 612866), whose protein product
adds the second GlcNAc to the growing LLO.65 In yeast,
Alg14 forms a multiglycosyltransferase complex with
Alg13 and Alg7 (DPAGT1) to generate the first two steps
in LLO synthesis.66,67 Similarly to DPAGT1 and GFPT1,
ALG14 is concentrated at the muscle motor endplates,
and siRNA knockdown of ALG14 reduces cell-surface
expression of ectopically expressed muscle AChR.65
Furthermore, mutations in ALG2 (MIM 607905),
which encodes LLO a-1,3-mannosyltransferase, also cause
CMSs.65 ALG2 levels both inmuscle and in cell cultures are
decreased in affected individuals.65 Studies in yeast have
shown that Alg1 (the first mannose in LLO synthesis) is
present along with Alg2 (the second and third mannoses)
and Alg11 (the fourth and fifth mannoses) in complexes,
suggesting that physical association of these sequential
catalytic enzymes in the ER membrane might improve
the efficiency of LLO synthesis.68 Why these reported mu-
tations in DPAGT1, ALG14, and ALG2 manifest as CMSs
rather than themuchmore severe CDG clinical phenotype
is unclear, but it is likely that additional genes encoding
components of the LLO pathway will be associated with
CMSs.69
Perhaps hypotonia, a consistent feature of CDG cases
with N-glycosylation disorders, is caused by AChR defi-
ciency rather than a manifestation of the CNS. This is an
intriguing possibility and clinically important because
the DPAGT1 and GFPT1 CMS cases responded well to anti-
cholinesterase medication and drugs that increase acetyl-
choline release from the nerve terminals.61
O-Mannose Pathway: a-Dystroglycanopathies
Dystroglycanopathies are congenital muscular dystrophies
(CMDs) that result from defective O-mannosylation of6, 2014
a-DG. a-DG and b-dystroglycan (b-DG) arise from proteo-
lytic cleavage of dystroglycan (encoded by DAG1 [MIM
128239]) and form two noncovalently associated sub-
units.70 a-DG primarily serves as an extracellular periph-
eral glycoprotein and links the extracellular matrix to the
cytoskeleton through a physical association with b-DG
and laminin (encoded by LAMA2 [MIM 156225]).70 The
degree and type of a-DG glycosylation can vary between
different tissues, but dystroglycanopathies often manifest
with significant pathology in the muscles, nerves, heart,
eyes, and brain.70 Given that clinically diverse forms of
CMD can arise from mutations within the same gene, a
modified CMD nomenclature that specifically focuses on
a-DG glycosylation (the muscular dystrophy dystroglycan-
opathy [MMDG] classification) has been developed. This
classification scheme is based on the order in which the
gene was identified and a severity scale, in which A, B,
and C represent sever, intermediate, and mild, respectively
(Table S1).
Monoclonal antibodies that recognize the O-mannose
glycans on a-DG have been a useful tool for identifying
these glycosylation-related defects (Table 1). Although
the analysis of glycan structures and their biosynthesis
on a-DG is incomplete, significant progress has occurred.
For example, recent work has shown that LARGE (MIM
603590; mutations cause MDDG type A6 [MIM 613154])
encodes a copolymerase that adds a variable number of
alternating a1,3-Xyl and b1,3-GlcUA units to a-DG.25
The location of the copolymer on the O-mannose glycan,
however, remains unknown.
Walker Warburg syndrome (WWS) refers to a group of
dystroglycanopathies clinically characterized by both
abnormal brain and eye structures and CMD. WWS is the
most severe dystroglycanopathy, and because it is a clinical
diagnosis, mutations in several genes in the pathway can
produce a similar phenotype. POMT1 and POMT2 account
for ~50% ofWWS cases, butmutations in additional genes,
including POMGNT2 (also known as GTDC2 [MIM
614828]) and TMEM5 (MIM 605862), have been discov-
ered by exome sequencing.71,72 TMEM5 has a glycosyl-
transferase domain (GTD) motif similar to that of glycosyl-
transferase EXT1, which is a bifunctional enzyme that
polymerizes the repeating disaccharides in heparan sulfate
biosynthesis, but how TMEM5 affects glycosylation is
currently unclear. For better understanding the physiolog-
ical function of GTDC2, morpholino knockdown of zebra-
fish gtdc2 was used for reproducing the WWS phenotype;
subsequently, biochemical analysis indicated that GTDC2
is an O-linked mannose b1,4-N-acetylglucosaminyltrans-
ferase.73
Exome sequencing and genetic mapping of undiagnosed
WWS cases identified several mutations in isoprenoid syn-
thase domain containing (ISPD [MIM 614631]), encoding a
protein that is uncharacterized in humans.74,75 Two
different methods were used for confirming that ISPDmu-
tations cause WWS. Willer et al.74 performed complemen-
tation assays in which glycosylated a-DG served as aThe Americbiomarker readout on fibroblasts obtained from affected
individuals, and Roscioli et al.75 utilized morpholino
knockdowns in zebrafish. How ISPD affects glycosylation
of a-DG remains unclear, but one hypothesis is that it is
necessary for the synthesis of a unique nucleotide sugar
required for O-glycosylation.
Many of the 14 genes in which mutations cause
a-dystroglycanopathies encode putative or demonstrated
glycosyltransferases (Table S1). More recently, mutations
have been identified in several genes that encode proteins
used in the formation of Dol-P-Man required for O-manno-
sylation, including DOLK and the DPM1-3 complex.13
DOLK is required for phosphorylation of dolichol, andmu-
tations in DOLK (MIM 610746) cause a severe CDG that
frequently causes premature death.76 Moreover, homozy-
gosity mapping in consanguineous families has shown
that DOLK mutations cause dilated cardiomyopathy
(DCM), given that biopsied heart tissue in these individ-
uals showed reduced O-mannosylation of a-DG.77
The DPM complex is required for Dol-P synthesis and is
composed of DPM1 (the catalytic subunit), DPM2 (the sta-
bilizing subunit), and DPM3 (the ER-targeting subunit).78
The clinical spectrum among the three disorders caused
by mutations in DPM1, DPM2, and DPM3 is broad (Table
S1). However, defective O-mannosylation of a-DG, along
with elevated creatine kinase levels most likely due to
decreased levels of Dol-P-Man, has been reported in both
DPM2 and DPM3 deficiencies.79,80 Not surprisingly, a
form of a-dystroglycanopathy was observed in an individ-
ual with a DPM1 deficiency in which the mutations re-
sulted in reduced activity but a complete loss of DPM1
binding to DPM3.81 Dystroglycanopathies involving the
Dol-P-Man pathway highlight the notion that these pro-
teins and probably many more are involved in multiple
glycosylation pathways.
Recently, Jae et al.82 used a clever haploid-genetic-
screening method that relied on the requirement of com-
plete a-DG glycosylation for Lassa virus entry to identify
additional genes affecting O-mannose glycosylation.83,84
They identified all previously known genes linked to a-dys-
troglycanopathies and many more involved in other
aspects of glycosylation and glycosylation-related genetic
disorders. Importantly, the screen also identified DPM1,
DPM3, and MPDU1 (MIM 604041), further highlighting
the importance of Dol-P-Man in dystroglycanopathies.
Several previously unreported glycosylation-relevant
candidate genes were also identified. Using their gene list
to probe unsolved WWS cases led to the identification of
deficiencies of both TMEM5 and POMK (also known as
SGK196 [MIM 615247], mutations in which cause CMD-
dystroglycanopathy with brain and eye anomalies type
A12 [MIM 615249]).82
Defects in the GPI-Anchor Pathway
Although the N-linked glycosylation pathway uses the
lipid carrier dolichol as a transient intermediate, proteins
bearing N-glycans do not include the lipid. This is notan Journal of Human Genetics 94, 161–175, February 6, 2014 167
true for the GPI-anchor pathway, where the lipid remains a
functional component of the protein acceptors. Disorders
involving nine GPI-anchor-biosynthesis-related proteins
have been identified mostly by a combination of auto-
zygosity mapping and exome sequencing (Table S1 and
Figure 3). These proteins include PIGA, PIGL, PIGM,
PIGN, PIGO, PIGV, PGAP2, PIGT, and most recently,
PIGW. Somatic mutations in the X-linked gene PIGA
were long known to cause the hematological disorder
paroxysmal nocturnal hemoglobinuria (MIM 300818),
which results in erythrocyte lysis,85 but a recent report
identified a neonatal-lethal germline PIGA mutation that
appeared to retain some residual activity.86 PIGL carries
out the second step of the GPI-anchor pathway, de-N-
acetylation of N-acetylglucosaminylphosphatidylinositol
(GlcNAc-PI), and the mutations in PIGL (MIM 605947)
cause CHIME (ocular coloboma, heart defects, ichthyosis,
mental retardation, and ear anomalies) syndrome (MIM
280000).87 PIGM is a mannosytransferase that adds the
first mannose to the core GPI.88 Diminished PIGM activity
causes venous thrombosis and seizures.41 Because muta-
tion in PIGM (MIM 610273) occurs at an SP1-transcrip-
tion-binding site, which results in histone hypoacetylation
of the promoter, the histone deacetylase inhibitor phenyl-
butyrate was used to increase acetylation and restore PIGM
transcription and GPI expression at the cell surface. More
importantly, a 2-week course of treatment with phenylbu-
tyrate reduced the frequency of seizures and improved the
motor skills of an individual with PIGM deficiency.89 PIGN
(MIM 606097) encodes the ethanolamine phosphate
transferase PIGN, which adds the ethanolamine phos-
phate to the first mannose on the GPI anchor. Mutations
in PIGN cause multiple congenital anomalies-hypotonia-
seizures syndrome (MIM 614080).90
Mutations in PIGV (MIM 610274) or PIGO (MIM
614730), encoding a ethanolamine phosphate transferase,
cause hyperphosphatasia with mental retardation syn-
drome (HPMRS1 [MIM 239300] and HPMRS2 [MIM
614749]).91,92 The other GPI disorders do not result in
ALP secretion given that it requires removal of the C-termi-
nal GPI attachment-signal peptide for GPI addition. De-
fects producing shorter, nonmannosylated GPI chains
result in ALP degradation, but mannose-containing,
incomplete chains allow secretion.42
Mutations in PGAP2 (MIM 615187), encoding the non-
catalytic subunit of the GPI lipid-remodeling complex
(located in the Golgi), were recently described in two pa-
pers. Using a targeted exome sequencing panel, Krawitz
et al. identified two unrelated cases with mutations in
PGAP2 among 13 individuals with abnormal neurological
features such as seizures, hypotonia, variable intellectual
disability, and hyperphosphatasia (HPMRS3 [MIM
614207]).93 Expression of the wild-type, but not mutant,
allele restored CD55 and CD59 expression to normal levels
in PGAP2-deficient Chinese hamster ovary (CHO) cell
lines. ALP release in cases of PIGV and PIGO deficiency dif-
fers from that in PGAP2 deficiency given that secretion168 The American Journal of Human Genetics 94, 161–175, Februaryoccurs because of incomplete fatty-acid exchange. In the
second study, Hansen et al. used autozygosity mapping
and deep sequencing to identify seven cases with PGAP2
mutations that did not rescue expression of GPI-anchored
proteins in the same CHO-deficient cell line used by Kra-
witz et al. In contrast, however, they obtained complete
phenotypic rescue by using mutant alleles when their
expression was driven by a strong promoter, implying
that the mutations were hypomorphic.94 They also found
that the phenotype can be restricted to only intellectual
disability with elevated ALP. The phenotypic severity
might depend on the location of the mutated gene in the
biosynthetic pathway or on the severity of the mutation
in the individual genes. The latter point is well illustrated
by the multigene basis of the clinically severe WWS.
PIGT (MIM 610272) encodes one of the subunits of the
transamidase complex, which attaches the anchor to the
recipient proteins. Four individuals from a consanguin-
eous kindred carried homozygous mutation c.547A>C
(p.Thr183Pro) in PIGT (RefSeq accession number
NM_015937.5). All the cases shared distinct facial features,
intellectual disability, hypotonia, seizures, and multiple
ocular and cardiac abnormalities. Similarly to cases of
hypophosphatasia, they also showed bone and tooth ab-
normalities with low serum ALP.95 Granulocytes from the
cases had reduced levels of the GPI client CD16b, and
whereas expression of the wild-type human allele rescued
morpholino knockdown of the zebrafish ortholog of
PIGT, the mutant allele was unable to do so.
O-Fucose and O-GlcNAc Pathways: Notch-Related
Glycosylation
Dowling-Degos disease (MIM 179850) is a rare autosomal-
dominant skin disorder characterized by reticulate
hyperpigmentation and hypopigmentation at flexure
regions such as the neck, axilla, and areas below the
breasts and groin.96 Nonsense and deletion mutations in
POFUT1 (MIM 607491), encoding a Notch-modifying
O-fucosyltransferase, can cause this disorder.94 Previous
studies in mice have shown that O-fucosylation of Notch
controls receptor-ligand interactions that influence
lymphoid and myeloid homeostasis97,98 and other critical
aspects of development.99 Haploinsufficiency combined
with high demand and expression in melanocytes prob-
ably account for this specific and relatively mild pheno-
type. Morpholino knockdown in zebrafish embryos
showed hypopigmentation, reduced abnormal melanin
distribution, and up to a 45% decrease in tyrosinase activ-
ity in morphants.
Autosomal-recessive forms of Adams-Oliver syndrome
cause aplasia cutis congenita and terminal transverse
limb defects (MIM 100300). Autozygosity mapping of
five individuals from multiple consanguineous families re-
vealed the presence of homozygous frameshift, deletion,
or missense mutations in EOGT (MIM 614789).100 These
mutations led to consistent scull and scalp defects, loss of
phalanges, and hypoplastic nails. An accumulation of6, 2014
Table 2. Filtering Criteria for Variants in 53 Genes in which Mutations Cause Glycosylation Disorders
Filtering Criteria
GERP102 PolyPhen-2 Provean
Highest Population Allele
Frequency in 1000
Genomes or ESP6500
Total No. of Variants
Passing Filters
Strict R5 R0.95 deleterious %0.1 289
Moderate R4 R0.95 deleterious %1.0 525
Loose R3 R0.85 deleterious %2.0 618
Filtering criteria were applied to nonsense, missense, splice, and frameshift variants present in 1,828 EAs and 1,828 AAs randomly selected from the ESP6500 data
set after the exclusion of individuals with a call rate < 90% for variants in the 53 CDG-associated genes studied. Genotypes were zeroed out if quality was <20,
genotype quality was <20, and depth was <8 or >250. Variants were annotated with SeattleSeq137 and excluded if given a functional annotation of any of the
following: intron, UTR, 30 UTR, 50 UTR, coding synonymous, or coding synonymous near splice. The PolyPhen-2 and Provean algorithms do not provide predic-
tions for nonsense or splice-site variants, so such variants were automatically treated as if both algorithms predicted a deleterious outcome.103,104Eogt mRNA was found in the digit-condensation region in
embryonic day 12.5 mice, supporting the idea that Eogt
loss causes a deficiency in cell-cell or cell-matrix interac-
tions or in Notch-related signaling. This study revealed
two important points: (1) extracellular (trafficked through
the ER and Golgi) proteins other than Notch carry
O-GlcNAc and could account for the phenotype, and (2)
Golgi-localized EOGT is not related to cytoplasmic or nu-
clear OGT (encoded by OGT [MIM 300255]), which is
well known to modify hundreds of cytoplasmic proteins
and control intracellular signaling, especially in response
to nutrition and stress.101 Confusion is easy when different
glycosyltransferases catalyze the identical reaction by us-
ing the same donor (UDP-GlcNAc) but have different
acceptor substrates located in different cellular compart-
ments. Moreover, O-GlcNAcase, which readily cleaves
O-GlcNAc from cytoplasmic O-GlcNAcylated proteins, is
not known to function in the Golgi or outside the cell.
Frequency of Glycosylation Disorders
The prevalence and carrier frequencies of most individual
CDGs, and of CDGs collectively, are unknown. Given
our increasing knowledge of genes and variants that cause
CDGs, one approach to estimating the overall frequency of
CDGs is to infer the number of heterozygous carriers in the
general population. To this end, we used the NHLBI Exome
Sequencing Project ESP6500 data set to identify potentially
pathogenic missense, splice, nonsense, and frameshift var-
iants in 53 genes in which mutations are known to cause a
CDG.
Exome variants (Table S3) in samples from 1,828 Euro-
pean Americans (EAs) and an equal number of African
Americans (AAs) were filtered for potentially pathogenic
variants (Table 2), whose criteria included level of conser-
vation, predicted deleteriousness, and frequency of the
alternate allele in outbred populations (1000 Genomes
and the ESP6500).103,104 Filtering parameters were varied
(strict, moderate, and loose) for the generation of three
different data sets of predicted pathogenic variants.
To evaluate the performance of these parameters, we
applied this filtering strategy to ESP6500 variants identi-
fied in 39 genes in which mutations cause inborn errorsThe Americof metabolism as assessed by the Washington State
Newborn Screening program (i.e., NBS gene set). We
compared the set of predicted pathogenic variants in these
39 genes to 371 true pathogenic and 95 nonpathogenic
variants determined by manual curation (M.J.B., unpub-
lished data). Usingmoderate filter parameters, we excluded
39% of the true pathogenic variants in the NBS gene set
(i.e., false negatives) and included 18% of the nonpatho-
genic variants in the NBS gene set (i.e., false positives).
Under strict and loose filter parameters, the false-negative
rates were 64% and 30%, respectively, and the false-posi-
tive rates were 6% and 23%, respectively. Furthermore,
33 reported CDG mutations (in OMIM or HGMD, Public
version) were identified among the ESP6500 variants. Of
these mutations, 15 passed the strict filters, 32 passed the
moderate criteria, and all 33 passed the loose criteria. These
results demonstrate that the three filters balance specificity
and sensitivity and that the use of a moderate filter is fairly
conservative, that is, it most likely underestimates the
number of true pathogenic variants.
With moderate filter parameters, 20.7% and 26.3% of
EAs and AAs, respectively, carried at least one predicted
CDG allele (Figure 4). EAs carried an average of 0.29 alleles
(range ¼ 0.097–0.49), whereas the average in AAs was 0.45
alleles (range ¼ 0.10–0.65). These results indicate that,
overall, ~20% of individuals in the United States have at
least one allele that would cause abnormal glycosylation
and that the carrier frequency of these variants might be
higher in AAs than in EAs. Next, we calculated the ex-
pected frequency of individuals who were either a com-
pound heterozygote or homozygote for a predicted patho-
genic variant for each of the genes in which mutations are
known to cause a CDG (Figure 5). These results predicted
an overall CDG prevalence of ~1/1,000 in EAs and
~2/1,000 in AAs under moderate filters, ~4/1,000 in EAs
and 5/1,000 in AAs under loose filters, and 1/10,000 in
both EAs and AAs under strict filters. These estimates of
overall prevalence are higher than expected according to
published estimates of prevalence and anecdotal experi-
ence (~1/20,000 for the most prevalent subtype, PMM2-
CDG). The validity of the approach is evident from the
following predictions, which show that severalan Journal of Human Genetics 94, 161–175, February 6, 2014 169
AB
Figure 4. Burden of Putatively Delete-
rious Alleles in Glycosylation-Pathway
Genes
We queried 1,828 EAs (A) and 1,828 AAs
(B) in the ESP6500 data set. Strict filtering
criteria for identifying putatively delete-
rious alleles are shown in black, and those
using moderate filtering criteria are high-
lighted in color. Under moderate filtering,
20.7% of EAs carry one predicted CDG
allele, 3.6% carry two alleles, and <1%
carry three or more alleles. In comparison,
26.3% of AA carry one allele, 6.9% carry
two alleles, 1.4% carry three alleles, and
<1% carry four or more alleles.glycosylation-related disorders are consistent with their re-
ported prevalence estimates:GALT (MIM 606999; 1/40,000
for galactosemia [MIM 230400] under moderate filters),
GALE (MIM 606953; 1/15,000 for galactose epimerase defi-
ciency [MIM 230350] under moderate filters), and PMM2
(1/20,000 under loose filters, including for the relatively
common pathological variant c.422G>A [p.Arg141His]
[RefSeq NM_000303.2]).
The discrepancy between the predicted and known prev-
alence of CDGs could be due to one of several factors alone
or in combination. First, some of the proteins encoded by
these genes could be tolerant of ‘‘deleterious’’ mutations
such that only a small fraction of putatively damaging
alleles are actually pathogenic. For example, the estimates
of affected individuals with mutations in ALG6 (MIM
604566), ALG8 (MIM 608103), COG1 (MIM 611209), and
COG8 (MIM 606979) are unexpectedly high under loose
filter parameters. Second, for other genes, the loose
filtering criteria predict only slight increases over moderate
filters, possibly reflecting the limited ability of existing
strategies to make accurate functional predictions. Third,
homozygosity and/or compound heterozygosity for muta-
tions in some of these genes could be lethal during
embryogenesis, as supported by a recent report that all
the affected males with mutations in the X-linked gene
SLC35A2 are somatic mosaics. Finally, some alleles could
be incompletely penetrant or result in an unusual clinical
presentation, which could cause only a fraction of homo-
zygotes and/or compound heterozygotes to ever come to
medical attention. Most individuals with a CDG are diag-
nosed because of an abnormal transferrin test (Table 1).170 The American Journal of Human Genetics 94, 161–175, February 6, 2014However, not all CDGs, including
some of those in this analysis of pre-
dicted frequencies, are characterized
by an abnormal transferrin.1,12 More-
over, abnormal transferrin results can
resolve with age, particularly after in-
fancy.51 An affected individual with
normal transferrin would most likely
not be considered for further CDG
testing and might only be diagnosed
via the identification of pathogenicmutations in glycosylation-related genes. To this end, we
think that the increasing utilization of clinical exome
sequencing will most likely lead to the identification of
CDG-affected individuals who are mildly symptomatic or
have an atypical presentation.
Finally, we note the prediction of an almost two-fold
higher frequency of CDGs in AAs than in EAs. Indeed,
some CDGs that are extremely rare in EAs, such as those
caused by mutations in MPI (MIM 154550), ALG9 (MIM
606941), COG5 (MIM 606821), COG6 (MIM 606977),
and COG8, are predicted to be considerably more frequent
in AAs. In the case of MPI-CDG, this could have impor-
tant implications, given that it is the only CDG with an
effective treatment (dietary mannose supplements). The
explanation of this result is unclear. It might simply be
due to the higher absolute number of rare variants and
predicted functional variants observed in AAs. However,
the spectrum of CDG phenotypes and mutations that
cause CDGs in AAs versus EAs are less well known, so
there could be more as yet undiscovered CDG variants
in AAs.
Future Perspectives
The discovery of glycosylation disorders is rapidly acceler-
ating with the expanded use of exome sequencing. Priori-
tizing candidate genes is often a challenge, but it can be
facilitated by routine diagnostic testing of biomarkers
such as Tf. However, the sensitivity of biomarkers is
limited.12 Therefore, it will remain important to use func-
tional analysis and characterization to first determine
whether a variant(s) is causal and to then fully understand
AB
TOTAL
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× 10–4
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× 10–4
Figure 5. Expected Frequency of Individuals with Two Putatively Deleterious Alleles in 53 Glycosylation-Pathway Genes
EAs (A) and AAs (B). Strict filtering criteria for identifying putatively deleterious alleles are shown in black, andmoderate filtering criteria
are highlighted in color. Under moderate filtering, 9/10,000 EAs and 21/10,000 AAs are expected to carry two predicted CDG alleles in
one gene.its impact on glycosylation pathways. Mimicking patho-
logical features in zebrafish models either by creating mor-
phants or by showing that the mutant alleles poorly rescue
knockouts can help to validate predicted phenotypic con-
sequences. Development of targeted therapeutics will crit-
ically depend on understanding the mechanisms by which
glycosylation defects cause disease. For example, incom-
plete sugar chains could be either insufficient or toxic de-
pending on the cell type, the glycosylation and metabolic
load, and the expression of other genes that could offset
the deficiency. Indeed, this complexity oftenmakes it diffi-
cult to predict which cells, organs, and systems will be
most at risk from glycosylation defects.
Another pair of fundamental questions is how glycosyl-
ation affects signaling in the broadest sense—not only the
familiar signaling pathways but also those influenced by
metabolic flux of precursor sugars—and how glycosylation
affects the assembly of cell-surface signaling complexes.
Very little is known about either. However, as more glyco-
sylation disorders are discovered and characterized, this
should become clearer. Finally, we need to be cognizant
of developing effective ways for basic scientists and clini-
cians to partner in earnest to address these issues while
keeping in mind the best interests of the primary stake-
holders—the affected individuals and their families. We
are deeply indebted to them for making much of our
work possible and committed to finding ways to better
serve them.The AmericSupplemental Data
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